Metro Health - University of Michigan Health to Use Glytec’s Software for Inpatient Diabetes Care

WALTHAM, Mass.--(BUSINESS WIRE)-- Known for high-quality, personalized care and award-winning services, Metro Health - University of Michigan Health is taking inpatient diabetes management to the next level. With a decades-long focus on ensuring glucose control is a top priority, the healthcare organization has selected Glytec’s eGlycemic Management System^® (eGMS^®) to advance the standardization of best practice. The software-as-a-medical-device eGMS^® platform is both patented and FDA cleared.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190430005165/en/

“Our IT, clinical and administrative leaders work hand in hand to evaluate and select technology solutions that not only improve the quality and safety of patient care, but also improve processes and efficiencies for the clinicians who provide that care,” says J. Joshua Wilda, Executive Vice President, Chief Information Officer and Interim Chief Operating Officer for Metro Health - University of Michigan Health. “We feel that Glytec’s eGMS® meets these criteria, and the business case for clinical and financial improvement is compelling.” (Photo: Business Wire)

“We’ve been using an intravenous insulin dosing tool in our critical care units for a number of years,” says Dr. Ronald Grifka, Chief Medical Officer for Metro Health - University of Michigan Health. “Partnering with Glytec will allow us to support our patients and clinicians in a more comprehensive manner, with integrated solutions that address all areas of care, including subcutaneous basal-bolus insulin on the inpatient floors, where 90 percent of all insulin is administered.”

Approximately 30 to 40 percent of patients require insulin therapy during hospitalization, either because they have diabetes or their blood sugar becomes elevated due to the stresses of surgery or other acute conditions. Glytec’s solution will equip clinical care teams at Metro Health - University of Michigan Health with evidence-based, technology-enabled decision support to ensure both intravenous and subcutaneous insulin therapy are managed safely and effectively, according to standards established by the American Diabetes Association and American Association of Clinical Endocrinologists. The company will also provide a suite of expert professional services designed to help facilitate and support clinical practice change and ongoing quality improvement.

“With Glytec’s solution, we are positioning ourselves to achieve best practice for all patients. No matter what Metro floor or unit they’re treated on, no matter which of our clinicians is caring for them, every patient will receive the same level of excellent care,” says Grifka. “We will deliver personalized insulin therapy that is responsive to a patient’s changing needs, and dose adjustments will be made in a very timely and precise manner. This includes transitions from intravenous to subcutaneous insulin therapy -- when patients are transferred from critical care units to step-down or medical-surgical units -- as well as transitions from hospital to home. These measures will help reduce both length of stay and readmissions, consistent with many published studies of the eGMS^® platform.”

Glytec’s proprietary SmartClick^® technology for interoperability will give clinical care teams at Metro Health - University of Michigan Health ready access to eGMS^® from within the Epic electronic medical record. Other eGMS^® modules, such as GlucoSurveillance^®, GlucoView^® and GlucoMetrics^®, will provide hyperglycemia surveillance, glycemic status monitoring, robust analytics, reporting and more.

“Our IT, clinical and administrative leaders work hand in hand to evaluate and select technology solutions that not only improve the quality and safety of patient care, but also improve processes and efficiencies for the clinicians who provide that care,” says J. Joshua Wilda, Executive Vice President, Chief Information Officer and Interim Chief Operating Officer for Metro Health - University of Michigan Health. “We feel that Glytec’s eGMS^® meets these criteria, and the business case for clinical and financial improvement is compelling.”

About Glytec

Founded in 2006, Glytec is the pioneer of digital therapeutics, improving the lives of people with diabetes by making insulin a more effective and accessible option for millions unable to achieve their treatment goals. The company’s patented eGlycemic Management System^® is the only FDA-cleared software-as-a-medical-device (SaMD) platform to enable the mass personalization of insulin across the continuum of care: inpatient, outpatient and virtual settings alike. Glytec offers several comprehensive programs combining evidence-based decision support technologies with expert professional services proven to aid providers in achieving best practices and standardization while reducing hyperglycemia, hypoglycemia, A1C, readmissions, length of stay and cost. The company has offices in Waltham, Massachusetts and Greenville, South Carolina. For more information visit www.glytecsystems.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190430005165/en/